Neomycin
- CAS No.
- 1404-04-2
- Chemical Name:
- Neomycin
- Synonyms
- neomas;neomin;neomcin;myacyne;neolate;Jernadex;NEOMYCIN;nivemycin;Bycomycin;Neomyacin
- CBNumber:
- CB3667633
- Molecular Formula:
- C23H52N6O25S3
- Molecular Weight:
- 908.88
- MDL Number:
- MFCD00131817
- MOL File:
- 1404-04-2.mol
- MSDS File:
- SDS
| Melting point | 250 °C (decomp) |
|---|---|
| storage temp. | 2-8°C |
| solubility | H2O: 50 mg/mL As a stock solution. Stock solutions should be filter sterilized and stored at 2-8°C. Stable at 37°C for 5 days. |
| form | powder |
| Stability | Hygroscopic |
| FDA 21 CFR | 556.430; 558.4 |
| EWG's Food Scores | 4 |
| FDA UNII | I16QD7X297 |
| NCI Drug Dictionary | neomycin |
| ATC code | A01AB08,A07AA01,A07AA51,B05CA09,D06AX04,J01GB05,R02AB01,S01AA03,S02AA07,S03AA01 |
| EPA Substance Registry System | Neomycin (1404-04-2) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Warning |
| Hazard statements | H361-H373 |
| Precautionary statements | P260-P314-P501-P201-P202-P281-P308+P313-P405-P501 |
| Hazard Codes | Xn |
| Risk Statements | 42/43 |
| Safety Statements | 22-36/37-45 |
| WGK Germany | 3 |
| RTECS | QP4375000 |
| F | 3-8-10 |
| Toxicity | LD50 oral in rat: 2750mg/kg |
Neomycin price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Usbiological | N2009-02 | Neomycin | 1404-04-2 | 500ul | $393 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb593424 | NEOMYCIN SULFATE | 1404-04-2 | 50μg | $425 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb593424 | NEOMYCIN SULFATE | 1404-04-2 | 100μg | $635.8 | 2021-12-16 | Buy |
| Biorbyt Ltd | orb593424 | NEOMYCIN SULFATE | 1404-04-2 | 500μg | $957.1 | 2021-12-16 | Buy |
Neomycin Chemical Properties,Uses,Production
Description
Neomycin is an antibiotic from the aminoglycoside group, and has two isomers - neomycin Band neomycin C. Occupational contact dermatitis mainly occurs in workers at animal-feed mills, in veterinaries and in health workers.
Originator
Myciguent,Upjohn,US,1951
Uses
Antibacterial; antifungal.
Uses
Neomycin is an antibiotic.
Uses
Neomycin, like streptomycin, has a broad spectrum of antibacterial activity. It is effective
with respect to the majority of Gram-negative and a few Gram-positive bacteria; staphylococci, pneumococci, gonococci, meningococci, and stimulants of dysentery. It is not very
active with respect to streptococci. The antibiotic effect of neomycin with respect to many
types of bacteria is higher than that of streptomycin. At the same time, microorganisms
sensitive to neomycin become resistant to a lesser degree than streptomycin.
It is used for various gastrointestinal diseases caused by microorganisms sensitive to it,
including enteritis, which is caused by microbes that are resistant to antibiotics. However,
because of its high oto- and nephrotoxicity, its local use is preferred for infected skin diseases, infected wounds, conjunctivitis, keratitis, and others. Synonyms of this drug are
framycetin, soframycin, tautomycin, and others.
Definition
An antibiotic complex obtained from Streptomyces fradiae; it is soluble in water and methanol but insoluble in most organic solvents. It consists of three component substances, all of which function as antiinfective agents; some derivatives have fungicidal properties. The three types are A (also called neamine): C12H26N4O6; B: C 23H46N6O13 (also available as hydrochloride and sulfate); and C: C23H46O13
Manufacturing Process
Neomycin has been produced by growing the organism, Strepromyces No.
3535, in a suitable nutrient medium under appropriate stationary or
submerged aerobic (viz shaken) conditions, and then isolating and purifying
the substance, e.g., by procedure of the sort described in the figure including
various steps of adsorption, recovery by elution, separation from impurities,
and precipitation.
Neomycin is usually used as the sulfate.
brand name
Mycifradin (Pharmacia & Upjohn); Neo-Fradin (X Gen); Neobiotic (Pfizer).
Therapeutic Function
Antibacterial
Antimicrobial activity
Among other organisms susceptible in vitro (MIC 4–8 mg/L) are Pasteurella, Vibrio, Borrelia and Leptospira spp. It is active against M. tuberculosis, including streptomycin-resistant strains. Synergy has been reported with polymyxin B. The bactericidal effect is enhanced at alkaline pH.
Acquired resistance
Resistance is acquired in a stepwise fashion and staphylococci may become resistant as a result of prolonged topical use. The use of neomycin–bacitracin–polymyxin mixtures may contribute to this, as many strains resistant to neomycin are also resistant to bacitracin. Resistant enterobacteria may appear in the feces of patients treated orally and in those treated for prolonged periods; most have been found to possess multiple transferable antibiotic resistance. Cross-resistance with kanamycin is often due to the synthesis of APH(3′), although AAC(6′) some forms of AAC(3) and ANT(4′) also modify both neomycin and kanamycin. Resistant strains of Staph. aureus are usually more resistant to kanamycin than to neomycin. The rare enzyme AAC(1) confers resistance to neomycin and paromomycin, but not to other aminoglycosides.
Contact allergens
Neomycin is an antibiotic complex of the aminoglycosides group, extracted from Streptomyces fradiae. It is composed of neomycin A (neamin) and an isomer neobiosamin, either neomycin B (framycetin or Soframycin?) or neomycin C. Its use has been progressively forbidden in cosmetics and as an additive for animal feed. Occupational contact dermatitis occurs in workers at animal feed mills, in veterinaries, or in health workers. Nonoccupational dermatitis mainly concerns patients with chronic dermatitis, leg ulcers, or chronic otitis. Cross-sensitivity is usual with other aminoglycosides (amikacin, arbekacin, butirosin, dibekacin, gentamicin, isepamicin, kanamycin, paromomycin, ribostamycin, sisomycin, tobramycin), is rare with netilmicin and streptomycin, but nonexistent with spectinomycin.
Mechanism of action
Neomycin has a wide spectrum of antibacterial action. It is effective against both a number of Gram-positive as well as Gram-negative microorganisms. However, it is able to bind with cholesterol and bile salts. In combination with other bile salt-reducing drugs or nicotinic acid, neomycin is able to block cholesterol and bile salt absorption, which significantly increases the level of cholesterol in the plasma.
Pharmacokinetics
Cmax 0.5 g intramuscular: 20 mg/L after 1 h
Plasma half-life: 2–3 h
Volume of distribution: 0.25–0.35 L/kg
Plasma protein binding: Low
Very little is absorbed after oral administration and more
than 95% is eliminated unchanged in the feces. Peak plasma
concentrations of less than 4 mg/L have been found after an
oral dose of 3 g. Distribution and excretion resemble that of
streptomycin, but the toxicity of neomycin precludes systemic
administration except in the most extreme cases.
Clinical Use
Superficial infections with staphylococci and Gram-negative bacilli
(topical; alone or in combination with bacitracin, chlorhexidine or
polymyxin)
Treatment of staphylococcal nasal carriers (topical, in combination with
chlorhexidine or bacitracin)
Eye infections (topical; alone or in combination)
Otitis externa (alone or with a corticosteroid)
Gut decontamination before abdominal surgery (oral)
Prophylaxis after urinary tract instrumentation (instillation)
Use is discouraged because of the possibility of promoting the
appearance of aminoglycoside-resistant strains, and because
of the risk of absorption with the consequent danger of systemic
toxicity or neuromuscular blockade.
Side effects
Neomycin is the most likely of all the aminoglycosides to
damage the kidneys and the auditory branch of the eighth
nerve. This has almost entirely restricted it to
topical and oral use.
Irreversible deafness may develop even if the drug is
stopped at the first sign of damage. Loss of hearing may occur
as a result of topical applications to wounds or other denuded
areas, particularly if renal excretion is impaired. Instillation
of ear drops containing neomycin can result in deafness. This
generally develops in the second week of treatment and is usually
reversible.
Rashes have been described in 6–8% of patients treated
topically and these patients may be rendered allergic to
other aminoglycosides. Nausea and protracted diarrhea may
follow oral administration. Sufficient drug may be absorbed
from the gut on prolonged oral administration to produce
deafness but not renal damage. Intestinal malabsorption and
superinfection have been seen in patients receiving 4–9 g
per day and may develop in patients receiving as little as 3 g
of the drug per day. Precipitation of bile salts by the drug
may impair the hydrolysis of long-chain triglycerides. Large
doses instilled into the peritoneal cavity at operation may be absorbed, with resultant systemic toxicity, and patients concurrently
exposed to anesthetics and muscle relaxants are
liable to suffer neuromuscular blockade, which is reversible
by neostigmine.
Safety Profile
Poison by intraperitoneal, intravenous, and subcutaneous routes. Moderately toxic by ingestion. Human systemic effects: changes in hearing acuity, liver tubule changes, and decreased urine volume or anuria. Mutation data reported. When heated to decomposition it emits acrid smoke and irritating fumes.
Synthesis
Neomycin is a complex mixture of antibiotics (neomycins A, B, C, D, E, and F), that is formed by the actinomycete S. fradiae. Neomycin A, also called neamine, is 2-deoxy-4-O-(2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl)-D-streptamine (32.4.2), and it does not display antibiotic properties. At the same time, neomycin B, O-2,6-diamino- 2,6-dideoxy-α-D-glucopyranosyl(1→4)-O-[O-2,6-diamino-2,6-dideeoxy-β-L-idopyranosyl-(1→3)-β-D-ribofuranosyl-(1→5)]-2-deoxy-D-streptamine (32.4.3), differs from neomycin A in the presence a second glycoside residue and exhibits powerful antibacterial activity. Neomycin C (32.4.4) differs from neomycin B in the orientation of the aminomethyl group in the neozamine part of the molecule.
Neomycin Preparation Products And Raw materials
Neomycin Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Hebei Mojin Biotechnology Co., Ltd | +8613288715578 | sales@hbmojin.com | China | 12471 | 58 |
| Hangzhou ICH Biofarm Co., Ltd | +undefined8613073685410 | sales@ichemie.com | China | 985 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21689 | 55 |
| Hebei Guanlang Biotechnology Co., Ltd. | +86-19930503282 | alice@crovellbio.com | China | 8822 | 58 |
| Shanghai Longyu Biotechnology Co., Ltd. | +8615821988213 | info@longyupharma.com | China | 2531 | 58 |
| career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | ada@ipurechemical.com | China | 10326 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | 0551-65418671 | sales@tnjchem.com | China | 34572 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-029-89586680 +86-18192503167 | 1026@dideu.com | China | 9126 | 58 |
| Hebei Qige Biological Technology Co. Ltd | +86 +8618733132031 | CHINA | 1313 | 58 |
Related articles
- Toxicity of Neomycin
- Neomycin is an aminoglycoside compound that is relatively toxic and therefore not used systemically. Neomycin was first descri....
- Mar 15，2022
View Lastest Price from Neomycin manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2023-11-01 | Neomycin
1404-04-2
|
US $0.00-0.00 / kg | 0.1kg | 99% | 500kg | Hangzhou ICH Biofarm Co., Ltd | |
 |
2023-09-08 | neomycin
1404-04-2
|
US $0.00 / KG | 1KG | 99% | 50000KG/month | Hebei Mojin Biotechnology Co., Ltd | |
 |
2023-03-06 | Neomycin Sulfate
1404-04-2
|
US $10.50 / KG | 1KG | 99 | 1 ton | Hebei Guanlang Biotechnology Co,.LTD |
-
- Neomycin
1404-04-2
- US $0.00-0.00 / kg
- 99%
- Hangzhou ICH Biofarm Co., Ltd
-
- neomycin
1404-04-2
- US $0.00 / KG
- 99%
- Hebei Mojin Biotechnology Co., Ltd
-
- Neomycin Sulfate
1404-04-2
- US $10.50 / KG
- 99
- Hebei Guanlang Biotechnology Co,.LTD
1404-04-2(Neomycin)Related Search:
1of4